A5071746125- Diabetes Management and Research
- Pancreatic function and diabetes
- Diabetes and associated disorders
- Metabolism, Diabetes, and Cancer
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diabetes Treatment and Management
- Parkinson's Disease Mechanisms and Treatments
- Cardiovascular Health and Risk Factors
- Pain Mechanisms and Treatments
- Botulinum Toxin and Related Neurological Disorders
- Cardiovascular Health and Disease Prevention
- Blood Pressure and Hypertension Studies
- Artificial Intelligence in Healthcare
Group for the Analysis of Development
2023-2025
Diabetes Care Center
2020-2023
Hyattsville Community Development Corporation
2019
High Point University
2018
Adolescents and young adults with type 1 diabetes exhibit the worst glycemic control among individuals across lifespan. Although continuous glucose monitoring (CGM) has been shown to improve in adults, its benefit adolescents not demonstrated.To determine effect of CGM on diabetes.Randomized clinical trial conducted between January 2018 May 2019 at 14 endocrinology practices US including 153 aged 24 years screening hemoglobin A1c (HbA1c) 7.5% 10.9%.Participants were randomized 1:1 undergo...
OBJECTIVE Despite advances in exogenous insulin therapy, many patients with type 1 diabetes do not achieve acceptable glycemic control and remain at risk for ketosis insulin-induced hypoglycemia. We conducted a randomized controlled trial to determine whether TTP399, novel hepatoselective glucokinase activator, improved people without increasing hypoglycemia or ketosis. RESEARCH DESIGN AND METHODS SimpliciT1 was phase 1b/2 adaptive study. Phase 2 activities were two parts. Part randomly...
TTP399 is an oral liver selective Glucokinase Activator (GKA). Because it exhibits insulin-independent mechanism of action, may be suitable as adjunctive treatment for type 1 diabetes (T1DM). In clinical trials in 2 (T2DM), has shown significant reduction postprandial glucose, increased percentage time range and decreased hypo or hyperglycemia. Moreover, significantly reduced HbA1c without hypoglycemia, dyslipidemia, ketoacidosis. The Simplici-T1 trial (NCT03335371) adaptive three-part...
Objective. To further evaluate glycemic outcomes during the observational extension phase of Continuous Glucose Monitoring (CGM) Intervention for Teens and Young Adults randomized clinical trial (RCT). Subjects Methods. Following a 26-week RCT comparing CGM with blood glucose monitoring (BGM) in 153 adolescents young adults aged 14 to <25 years old suboptimally controlled type 1 diabetes, 70 (89%) participants BGM group initiated use (referred as BGM–CGM cohort), (95%) continued (CGM–CGM...
Type 1 (T1D) and type 2 (T2D) diabetes are distinct diseases, but most federal surveys used to monitor prevalence have not included questions on type. To design validate survey that will distinguish between T1D T2D in adults, we developed a sample whom first determined "gold standard" for from review of electronic health record (EHR) data. From &gt;50,000 adult patients the UNC Health Care System with diabetes, assembled 2479 using "strawman" definition based diabetes-related diagnostic...